Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label Givinostat extension study in Duchenne muscular dystrophy
NL-OMON54775Phase 3Recruiting
- Sponsor
- CROMSOURCE
- Start
- Jan 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of givinostat in Duchenne muscular dystrophy (DMD) (3 arms), sponsored by CROMSOURCE. Primary endpoint: Treatment-emergent adverse events and serious adverse events. Started Jan 2020; status: recruiting.
02
Drugs
givinostat
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NL-OMON54775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54775.